Table 1.

Demographic and clinical characteristics of MS patients and control subjects

Patient	Clinical course	MS	Age/sex	TP (h)	DD (y)	Type of lesion
						AL	AIL	IL
MS122	Short (DD ≤ 16 y)	SP	44/M	16	16			1
MS356		SP	45/F	10	16	1
MS408		SP	39/M	21	10	2	2
MS422		SP	58/M	25	13	1		1
MS371		SP	40/M	27	14	1
MS114		SP	52/F	12	15			1
MS163		SP	45/F	28	6	1
MS 154		SP	34/F	12	12	1	1	1
MS160		SP	44/F	18	16	4	1	1
MSD15		SP	38/M	nd	14	1
MSD70		SP	49/M	nd	13		2
MS318	Long (DD > 16 y)	SP	59/F	13	34	3	2
MS187		SP	57/F	13	27		1	1
MS404		SP	55/F	17	34	1	2	1
MS466		SP	65/F	25	36	1	1
MS406		SP	62/M	23	47	3
MS470		SP	64/F	nd	35	2	2	2
MS055		SP	47/F	15	32	2	1	3
MS330		SP	59/F	21	39			1
MSD58		SP	82/M	nd	62			1
MS383	Short (DD ≤ 17 y)	PP	42/M	17	17	3	1
MS325		PP	51/M	13	2	1
MS083		PP	54/M	13	13		1	2
MS094		PP	42/F	11	6	3	3	1
MS473		PP	39/F	9	13	4	2
MS216		PP	58/F	9	12	1
MS500		PP	50/M	32	8	5
MSD276		PP	40/F	nd	17		1
MS057	Long (DD > 17 y)	PP	77/F	9	47	1	1	1
MS168		PP	88/F	22	30	2		2
MS492		PP	66/F	15	31			1
MS398		PP	57/F	28	28			1
MS363		PP	42/M	20	27	2	3	1
CO22		Ct	69/F	33
CO72		Ct	72/M	26
CO73		Ct	71/M	29
CO74		Ct	84/F	22
PDCO23		Ct	78/F	23
PDCO28		Ct	84/F	11

CNS samples from MS patients provided by the UK MS Tissue Bank (London, UK, identified as MS) and Dame Ingrid V. Allen tissue collection (from Belfast, UK, identified as MSD)

AL active lesion, AIL mixed active/inactive lesion, Ct control, DD disease duration, F female, h hours, IL inactive lesion, M male, nd not determined, PP primary progressive, SP secondary progressive, TP time post-mortem, y years